Home › Head and Neck Cancer › Illinois › Chicago
Head and Neck Cancer clinical trials in Chicago, IL
12 studies for Head and Neck Cancer are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- University of Illinois Cancer Center, Chicago
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RecruitingPhase 2/3
- Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133), Chicago
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
RecruitingPhase 2/3
- University of Illinois Cancer Center, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- University of Illinois Cancer Center, Chicago
A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
RecruitingPhase 2
- The University of Chicago, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- University of Chicago, Chicago
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RecruitingPhase 2
- University of Chicago Comprehensive Cancer Center, Chicago
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
RecruitingPhase 2
- The University of Chicago, Chicago
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RecruitingPhase 1
- The University of Chicago, Chicago
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RecruitingPhase 1
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chicago
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
RecruitingPhase 1/2
- University of Illinois at Chicago, Chicago
About Head and Neck Cancer
Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes. Read the different symptoms of each type.
More about Head and Neck Cancer on MedlinePlus
Head and Neck Cancer trials in other cities
- Houston, TX30 studies
- New York City, NY23 studies
- Boston, MA23 studies
- Nashville, TN22 studies
- St. Louis, MO17 studies
- Pittsburgh, PA13 studies
- Dallas, TX13 studies
- Los Angeles, CA12 studies
- Durham, NC11 studies
- Baltimore, MD11 studies
- Washington, DC11 studies
- Miami, FL10 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.